Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Cancer Lett

Retrieve available abstracts of 42 articles:
HTML format

Single Articles

    July 2021
  1. LIU Q, Hua M, Zhang C, Wang R, et al
    NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1beta/Th1/IFN-gamma in acute myeloid leukemia.
    Cancer Lett. 2021 Jul 5. pii: S0304-3835(21)00299.
    PubMed     Abstract available

    May 2021
  2. TAVAKOLI SHIRAZI P, Eadie LN, Page EC, Heatley SL, et al
    Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Cancer Lett. 2021;512:28-37.
    PubMed     Abstract available

    April 2021
  3. LING Y, Xu N, Zhao K, Han L, et al
    Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia.
    Cancer Lett. 2021;510:59-66.
    PubMed     Abstract available

  4. LEE DH, Kang SH, Choi DS, Ko M, et al
    Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells.
    Cancer Lett. 2021;510:37-47.
    PubMed     Abstract available

  5. LI Y, Li Y, Yin J, Wang C, et al
    A mitophagy inhibitor targeting p62 attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
    Cancer Lett. 2021 Apr 13. pii: S0304-3835(21)00157.
    PubMed     Abstract available

    August 2020
  6. YANG W, Liu S, Li Y, Wang Y, et al
    Pyridoxine induces monocyte-macrophages death as specific treatment of acute myeloid leukemia.
    Cancer Lett. 2020 Aug 26. pii: S0304-3835(20)30432.
    PubMed     Abstract available

  7. ZHANG LP, Lu AD, Wu J, Jia YP, et al
    Expanded activated autologous lymphocyte infusions improve outcomes of low- and intermediate-risk childhood acute myeloid leukemia with low level of minimal residual disease.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30415.
    PubMed     Abstract available

    July 2020
  8. YANG H, Zhou H, Huang Z, Tao K, et al
    Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides.
    Cancer Lett. 2020;482:44-55.
    PubMed     Abstract available

    January 2020
  9. YUSENKO MV, Trentmann A, Andersson MK, Ghani LA, et al
    Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
    Cancer Lett. 2020 Jan 31. pii: S0304-3835(20)30053.
    PubMed     Abstract available

  10. FORGIONE MO, McClure BJ, Eadie LN, Yeung DT, et al
    KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
    Cancer Lett. 2020;469:410-418.
    PubMed     Abstract available

  11. WANG W, Jiang Z, Wang L, Wang A, et al
    All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30667.
    PubMed     Abstract available

    December 2019
  12. GUPTA P, Zhang GN, Barbuti AM, Xin Z, et al
    Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
    Cancer Lett. 2019 Dec 11. pii: S0304-3835(19)30606.
    PubMed     Abstract available

    November 2019
  13. GRANDJENETTE C, Schnekenburger M, Gaigneaux A, Gerard D, et al
    Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells.
    Cancer Lett. 2019 Nov 14. pii: S0304-3835(19)30572.
    PubMed     Abstract available

    October 2019
  14. WANG R, Feng W, Wang H, Wang L, et al
    Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
    Cancer Lett. 2019 Oct 24. pii: S0304-3835(19)30535.
    PubMed     Abstract available

  15. VICENTE C, Arriazu E, Martinez-Balsalobre E, Peris I, et al
    A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Cancer Lett. 2019 Oct 5. pii: S0304-3835(19)30498.
    PubMed     Abstract available

    July 2019
  16. HUANG S, Pan J, Jin J, Li C, et al
    Abivertinib, a novel BTK inhibitor: anti-leukemia effects and synergistic efficacy with Homoharringtonine in acute myeloid leukemia.
    Cancer Lett. 2019 Jul 13. pii: S0304-3835(19)30404.
    PubMed     Abstract available

  17. YANG Q, Chen K, Zhang L, Feng L, et al
    Synthetic Lethality of Combined AT-101 with Idarubicin in Acute Myeloid Leukemia via Blockade of DNA Repair and Activation of Intrinsic Apoptotic Pathway.
    Cancer Lett. 2019 Jul 10. pii: S0304-3835(19)30399.
    PubMed     Abstract available

  18. AKIYAMA H, Umezawa Y, Ishida S, Okada K, et al
    Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
    Cancer Lett. 2019;453:84-94.
    PubMed     Abstract available

    June 2019
  19. GAZI M, Moharram SA, Marhall A, Kazi JU, et al
    Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9-16].
    Cancer Lett. 2019 Jun 4. pii: S0304-3835(19)30301.

    April 2019
  20. NUNES RODRIGUES ALVES AP, Fernandes JC, Fenerich BA, Coelho-Silva JL, et al
    IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30267.
    PubMed     Abstract available

  21. DELLOMO AJ, Baer MR, Rassool FV
    Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
    Cancer Lett. 2019 Apr 3. pii: S0304-3835(19)30212.
    PubMed     Abstract available

    March 2019
  22. PETRICK LM, Schiffman C, Edmands WMB, Yano Y, et al
    Metabolomics of Neonatal Blood Spots Reveal Distinct Phenotypes of Pediatric Acute Lymphoblastic Leukemia and Potential Effects of Early-life Nutrition.
    Cancer Lett. 2019 Mar 20. pii: S0304-3835(19)30163.
    PubMed     Abstract available

    December 2018
  23. TANG YL, Sun X, Huang LB, Liu XJ, et al
    Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-kappaB/COX-2 signaling pathways.
    Cancer Lett. 2018 Dec 10. pii: S0304-3835(18)30703.
    PubMed     Abstract available

    October 2018
  24. ZHANG JM, Wang CC, Zhang GC, Jiang Q, et al
    ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation.
    Cancer Lett. 2018;442:193-201.
    PubMed     Abstract available

    September 2018
  25. WANG Y, Chen H, Chen J, Han M, et al
    The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.
    Cancer Lett. 2018;438:63-75.
    PubMed     Abstract available

    June 2018
  26. LEE YC, Wang LJ, Huang CH, Shi YJ, et al
    ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
    Cancer Lett. 2018 Jun 15. pii: S0304-3835(18)30417.
    PubMed     Abstract available

    May 2018
  27. ZHANG X, Zheng X, Yang H, Yan J, et al
    Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Cancer Lett. 2018 May 29. pii: S0304-3835(18)30367.
    PubMed     Abstract available

    April 2018
  28. ZHU L, Liu X, Pu W, Peng Y, et al
    tRNA-derived small non-coding RNAs in human disease.
    Cancer Lett. 2018;419:1-7.
    PubMed     Abstract available

  29. RYU S, Kim DS, Lee MW, Lee JW, et al
    Anti-leukemic effects of PPARgamma ligands.
    Cancer Lett. 2018;418:10-19.
    PubMed     Abstract available

    March 2018
  30. HU X, Mei S, Meng W, Xue S, et al
    CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30221.
    PubMed     Abstract available

  31. FARAONI I, Aloisio F, De Gabrieli A, Consalvo MI, et al
    The poly(adp-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by nf-kappab activation.
    Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30197.
    PubMed     Abstract available

    February 2018
  32. VELA M, Corral D, Carrasco P, Fernandez L, et al
    Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
    Cancer Lett. 2018 Feb 22. pii: S0304-3835(18)30172.
    PubMed     Abstract available

  33. HE Y, Sun L, Xu Y, Fu L, et al
    Combined inhibition of PI3Kdelta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    Cancer Lett. 2018;420:49-59.
    PubMed     Abstract available

  34. TORELLO CO, Shiraishi RN, Della Via FI, Castro TCL, et al
    Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model.
    Cancer Lett. 2018;414:116-126.
    PubMed     Abstract available

    January 2018
  35. DE COLA A, Franceschini M, Di Matteo A, Colotti G, et al
    N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.
    Cancer Lett. 2018;412:272-282.
    PubMed     Abstract available

    October 2017
  36. WEN S, Wang J, Liu P, Li Y, et al
    Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30650.
    PubMed     Abstract available

    September 2017
  37. COLLADO R, Puiggros A, Lopez-Guerrero JA, Calasanz MJ, et al
    Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30536.
    PubMed     Abstract available

  38. SADRAS T, Heatley SL, Kok CH, Dang P, et al
    Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
    Cancer Lett. 2017 Sep 1. pii: S0304-3835(17)30521.
    PubMed     Abstract available

    August 2017
  39. PRIGOZHINA TB, Szafer F, Aronin A, Tzdaka K, et al
    Fn14.TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
    Cancer Lett. 2017;400:99-109.
    PubMed     Abstract available

    July 2017
  40. MOHARRAM SA, Shah K, Khanum F, Marhall A, et al
    Efficacy of CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
    Cancer Lett. 2017 Jul 26. pii: S0304-3835(17)30455.
    PubMed     Abstract available

    April 2017
  41. ESPINOZA JL, Elbadry MI, Taniwaki M, Harada K, et al
    The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30288.
    PubMed     Abstract available

    February 2017
  42. PIAO J, Takai S, Kamiya T, Inukai T, et al
    Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Cancer Lett. 2017;386:131-140.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.